Skip to main content



The aim of ACT3 is to find out the best way to treat patients with early cancer of the anus (in tumours measuring 2 cm or less) after removal by local excision surgery. The study is testing a plan for patients who have a local removal (excision) of an early anal cancer.

Most patients (80-90%) do not require further treatment and have close observation after surgery. Some patients (10-20%) need extra treatment with a combination of radiotherapy and chemotherapy (chemoradiotherapy) if there are cancer cells close to the edge of the area that has been removed during surgery.

The aim of the trial is to look at whether the approach of either observation, or lower dose chemoradiotherapy after surgery is helpful at stopping early anal cancer from coming back.

ACT3 Recruitment

83 participants – recruitment closed 31/08/2023